RPG Life Sciences Limited has announced a leadership change within its broader corporate group, revealing that Deepak Shukla, who has been serving as Chief Executive – API Business, has ceased to be a Senior Management Personnel of the company. The transition comes as Shukla takes on the role of Chief Executive Officer at RPG Active Pharma Limited, the group’s wholly-owned subsidiary, effective from the close of business on August 14, 2026, with his appointment taking effect on August 15, 2026. The move underscores an internal realignment of leadership across core business units within the RPG ecosystem.
The reshuffle signals a strategic shift in how the RPG group is steering its API-focused capabilities across its enterprise. By assigning Shukla to the top helm of RPG Active Pharma Limited, the company appears to be aligning leadership more closely with its subsidiary-centric growth agenda, while still leveraging Shukla’s experience to drive performance in the API space. Such internal transitions are often seen as a mechanism to preserve continuity and leverage institutional knowledge as the group pursues its value creation across its manufacturing and R&D platforms.
As RPG Life Sciences navigates this change, the market and stakeholders will be watching how the group fills the leadership gap left behind in the API business and how the new subsidiary leadership may influence collaboration, resource allocation, and execution of market strategies. The development reflects a broader pattern in diversified Indian pharma groups where executive moves within the family of companies aim to synchronize strategy, ensure succession, and maintain momentum across critical growth engines.